Cardiovascular Revascularization Medicine
Volume 10, Issue 1 , Pages 58-59, January 2009

Bare metal stent thrombosis 13 years after implantation☆

Cleveland Clinic, Cleveland, OH, USA and VA Boston Healthcare System and Brigham and Women's Hospital, Boston, MA, USA

Received 17 April 2008; accepted 21 April 2008.

Abstract 

There has been a great deal of recent controversy regarding the risk of very late stent thrombosis with drug eluting stents, especially in the context of antiplatelet therapy cessation. We report a case of very late stent thrombosis of a bare metal stent initially implanted for treatment of a myocardial infarction. The patient presented thirteen years later with a recurrent myocardial infarction three days after discontinuing aspirin. Angiography demonstrated thrombotic occlusion and severe underlying restenosis of the stent. To our knowledge, this is the latest bare metal stent thrombosis described in the world medical literature.

Keywords: Myocardial infarction, Restenosis, Stent thrombosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Disclosures: Dr. Bhatt discloses the following relationships: Research Grants (directly to the institution) - Bristol Myers Squibb, Eisai, Ethicon, Sanofi Aventis, The Medicines Company; Honoraria (currently donated to non-profits) – Astra Zeneca, Bristol Myers Squibb, Centocor, Daiichi- Sankyo, Eisai, Eli Lilly, Glaxo Smith Kline, Millennium, Paringenix, PDL, Sanofi Aventis, Schering Plough, The Medicines Company, tns Healthcare; Speaker’s bureau (not current, over 2 years ago) – Bristol Myers Squibb, Sanofi Aventis, The Medicines Company; Consultant/Advisory Board (currently donated to non-profits) – Astra Zeneca, Bristol Myers Squibb, Cardax, Centocor, Cogentus, Daiichi-Sankyo, Eisai, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, McNeil, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, Sanofi Aventis, Schering Plough, The Medicines Company, tns Healthcare, Vertex; Expert testimony regarding clopidogrel (the compensation was donated to a non-profit organization); Cleveland Clinic Coordinating Center currently receives or has received research funding from: Abraxis, Alexion Pharma, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardionet, Centocor, Converge Medical Inc., Cordis, Dr. Reddy’s, Edwards Lifesciences, Esperion, GE Medical, Genentech, Gilford, GSK, Guidant, J&J, Kensey-Nash, Lilly, Medtronic, Merck, Mytogen, Novartis, Novo Nordisk, Orphan Therapeutics, P&G Pharma, Pfizer, Roche, Sankyo, Sanofi-Aventis, Schering-Plough, Scios, St. Jude Medical, Takeda, TMC, VasoGenix, Viacor. Dr. Bavry discloses the following: honoraria for consulting from The Frankel Group, Boston Scientific, Propagate Pharma, HRA, Marketing Research Services of Houston, Medical Marketing Conference, Hagen/Sinclair Research Recruiting, and KCI Partners.

PII: S1553-8389(08)00207-8

doi:10.1016/j.carrev.2008.04.003

Cardiovascular Revascularization Medicine
Volume 10, Issue 1 , Pages 58-59, January 2009

Article Tools

* Image Usage & Resolution